These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30320974)

  • 1. Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening.
    Meissner KA; Kronenberger T; Maltarollo VG; Trossini GHG; Wrenger C
    Chem Biol Drug Des; 2019 Mar; 93(3):300-312. PubMed ID: 30320974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
    Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
    PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ji X; Wang Z; Chen Q; Li J; Wang H; Wang Z; Yang L
    Molecules; 2022 Apr; 27(9):. PubMed ID: 35566023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
    Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
    Nezami A; Luque I; Kimura T; Kiso Y; Freire E
    Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
    Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
    J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure-based virtual screening and molecular dynamic simulation.
    Pandey RK; Narula A; Naskar M; Srivastava S; Verma P; Malik R; Shah P; Prajapati VK
    J Biomol Struct Dyn; 2017 Mar; 35(4):791-804. PubMed ID: 26984239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
    Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
    ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
    [No Abstract]   [Full Text] [Related]  

  • 9. Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.
    Chaudhary M; Singh V; Anvikar AR; Sahi S
    Curr Comput Aided Drug Des; 2016; 12(4):282-293. PubMed ID: 27449897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
    Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
    J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II.
    Jin H; Xu Z; Cui K; Zhang T; Lu W; Huang J
    Fitoterapia; 2014 Apr; 94():55-61. PubMed ID: 24468190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
    Dali B; Keita M; Megnassan E; Frecer V; Miertus S
    Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplasmodial activity of hydroxyethylamine analogs: Synthesis, biological activity and structure activity relationship of plasmepsin inhibitors.
    Kumar Singh A; Rajendran V; Singh S; Kumar P; Kumar Y; Singh A; Miller W; Potemkin V; Poonam ; Grishina M; Gupta N; Kempaiah P; Durvasula R; Singh BK; Dunn BM; Rathi B
    Bioorg Med Chem; 2018 Jul; 26(13):3837-3844. PubMed ID: 29983285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.
    McKay PB; Peters MB; Carta G; Flood CT; Dempsey E; Bell A; Berry C; Lloyd DG; Fayne D
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3335-41. PubMed ID: 21531557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azole-based non-peptidomimetic plasmepsin inhibitors.
    Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
    Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
    Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
    Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.
    Hodder AN; Sleebs BE; Czabotar PE; Gazdik M; Xu Y; O'Neill MT; Lopaticki S; Nebl T; Triglia T; Smith BJ; Lowes K; Boddey JA; Cowman AF
    Nat Struct Mol Biol; 2015 Aug; 22(8):590-6. PubMed ID: 26214367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Click Inspired Synthesis of Novel Cinchonidine Glycoconjugates as Promising Plasmepsin Inhibitors.
    Mishra N; Agrahari AK; Bose P; Singh SK; Singh AS; Tiwari VK
    Sci Rep; 2020 Feb; 10(1):3586. PubMed ID: 32108142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The zymogen of plasmepsin V from Plasmodium falciparum is enzymatically active.
    Xiao H; Bryksa BC; Bhaumik P; Gustchina A; Kiso Y; Yao SQ; Wlodawer A; Yada RY
    Mol Biochem Parasitol; 2014 Oct; 197(1-2):56-63. PubMed ID: 25447707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
    Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
    Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.